High Throughput ADME Screening: Practical Considerations, Impact on the Portfolio and Enabler of In Silico ADME Models

被引:61
作者
Hop, Cornelis E. C. A. [1 ]
Cole, Mark J. [1 ]
Davidson, Ralph E. [1 ]
Duignan, David B. [1 ]
Federico, James [1 ]
Janiszewski, John S. [1 ]
Jenkins, Kelly [1 ]
Krueger, Suzanne [1 ]
Lebowitz, Rebecca [1 ]
Liston, Theodore E. [1 ]
Mitchell, Walter [1 ]
Snyder, Mark [1 ]
Steyn, Stefan J. [1 ]
Soglia, John R. [1 ]
Taylor, Christine [1 ]
Troutman, Matt D. [1 ]
Umland, John [1 ]
West, Michael [1 ]
Whalen, Kevin M. [1 ]
Zelesky, Veronica [1 ]
Zhao, Sabrina X. [1 ]
机构
[1] Pfizer Global Res & Dev, Groton, CT 06340 USA
关键词
Absorption; ADME; data management; in silico; in vitro; mass spectrometry; metabolism; pharmacokinetics;
D O I
10.2174/138920008786485092
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Evaluation and optimization of drug metabolism and pharmacokinetic data plays an important role in drug discovery and development and several reliable in vitro ADME models are available. Recently higher throughput in vitro ADME screening facilities have been established in order to be able to evaluate an appreciable fraction of synthesized compounds. The ADME screening process can be dissected in five distinct steps: (1) plate management of compounds in need of in vitro ADME data, (2) optimization of the MS/MS method for the compounds, (3) in vitro ADME experiments and sample clean up, (4) collection and reduction of the raw LC-MS/MS data and (5) archival of the processed ADME data. All steps will be described in detail and the value of the data on drug discovery projects will be discussed as well. Finally, in vitro ADME screening can generate large quantities of data obtained under identical conditions to allow building of reliable in silico models.
引用
收藏
页码:847 / 853
页数:7
相关论文
共 36 条
[21]  
Poon GK, 1999, RAPID COMMUN MASS SP, V13, P1943, DOI 10.1002/(SICI)1097-0231(19991015)13:19<1943::AID-RCM736>3.0.CO
[22]  
2-P
[23]   A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes [J].
Riley, RJ ;
McGinnity, DF ;
Austin, RP .
DRUG METABOLISM AND DISPOSITION, 2005, 33 (09) :1304-1311
[24]   The influence of DMPK as an integrated partner in modern drug discovery [J].
Riley, RJ ;
Martin, IJ ;
Cooper, AE .
CURRENT DRUG METABOLISM, 2002, 3 (05) :527-550
[25]  
Rossi D.T., 2002, MASS SPECTROMETRY DR
[26]   Do drug metabolism and pharmacokinetic departments make any contribution to drug discovery? [J].
Smith, D ;
Schmid, E ;
Jones, B .
CLINICAL PHARMACOKINETICS, 2002, 41 (13) :1005-1019
[27]   Moving in silico screening into practice:: A minimalist approach to guide permeability screening!! [J].
Stoner, Chad L. ;
Troutman, Mathew ;
Gao, Hua ;
Johnson, Kjell ;
Stankovic, Charles ;
Brodfuehrer, Joanne ;
Gifford, Eric ;
Chang, Man .
LETTERS IN DRUG DESIGN & DISCOVERY, 2006, 3 (08) :575-581
[28]   Predicting drug metabolism -: An evaluation of the expert system METEOR [J].
Testa, B ;
Balmat, AL ;
Long, A ;
Judson, P .
CHEMISTRY & BIODIVERSITY, 2005, 2 (07) :872-885
[29]   Liquid chromatography/tandem mass spectrometric quantification with metabolite screening as a strategy to enhance the early drug discovery process [J].
Tiller, PR ;
Romanyshyn, LA .
RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2002, 16 (12) :1225-1231
[30]   ADMET in silico modelling:: Towards prediction paradise? [J].
van de Waterbeemd, H ;
Gifford, E .
NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (03) :192-204